Immunotherapy Response and Resistance in Patients with Advanced Uveal Melanoma

Author:

Maurer Alexander1,Clerici Giulio1,Schaab Jan1,Cheng Phil2,Mihic Daniela1,Mader Caecilia1,Messerli Michael1,Huellner Martin1,Dummer Reinhard1,Dimitriou Florentia1

Affiliation:

1. University Hospital of Zurich

2. University Hospital of Geneva

Abstract

Abstract

Background Metastatic uveal melanoma (mUM) is associated with poor prognosis. Treatment with ipilimumab/nivolumab has shown antitumor efficacy. Tebentafusp resulted in longer overall survival (OS) compared to investigator`s choice in a phase III study. The aim of this study is to describe the radiological response patterns with both treatments in association with the treatment outcome. Methods Patients with mUM treated with ipilimumab/nivolumab or tebentafusp with available radiological assessment per RECISTv1.1 and/or imPERCIST5. Disease outcome, landmark progression-free survival (PFS) and OS were reported. The same criteria were used to assess the liver-specific response. Results 14 patients were treated with ipilimumab/nivolumab; treatment efficacy for best overall response (BOR) per RECIST v1.1 and imPERCIST5 was similar for the PFS (p=0.37 and p=0.23) and OS (p=0.14 and p=0.23). Patients with complete metabolic response (CMR), partial metabolic response (PMR) and partial response (PR) had longer PFS by trend. Treatment efficacy at the liver was concordant with the overall treatment efficacy for the PFS and OS. 22 patients were treated with tebentafusp; BOR per imPERCIST5 and RECISTv1.1 did not differ for the PFS (p=0.48 and p=0.21, respectively) and OS (p=0.63 and p=0.32, respectively). The hepatic treatment efficacy was concordant with the overall treatment efficacy. Patients with liver SD as best response showed a significant OS benefit (p=0.045). Conclusion Comprehensive radiological response evaluation with both RECIST v1.1 and imPERCIST5 can synergistically provide with an accurate assessment of immunotherapy efficacy in mUM, but both methods display limitations. Further studies to investigate the mechanisms of response and resistance are required.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3